| Riarify (beclometasone/formoterol/glycopyrrolate) / Chiesi |
2021-001429-34: Utility of inhaled triple therapy to improve expiratory flow limitation in severe COPD exacerbations. |
|
|
| Ongoing | 3 | 80 | Europe | Inhalation solution, TRIMBOW 87 micrograms/5 micrograms/9 micrograms | University Hospital Mutua de Terrassa, Mutua Terrassa | Severe exacerbation of chronic obstructive pulmonary disease (COPD), Exacerbations of a lung disease called chronic obstructive pulmonary disease (COPD), Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
TRECOS, NCT06264674: Comparison Between CHF5993 pMDI 200/6/12,5mg HFA-152a VS CHF5993 pMDI 200/6/12,5mg HFA-134a in Subjects With Asthma (Trecos) |
|
|
| Recruiting | 3 | 790 | Europe | CHF5993 200/6/12.5 μg pMDI HFA-152a, HFA-152a propellant, Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a, HFA-134a propellant | Chiesi Farmaceutici S.p.A. | Asthma | 08/24 | 09/25 | | |
TRITON, NCT04320342 / 2020-002389-16: A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD |
|
|
| Recruiting | 3 | 2934 | Europe, Canada, US, RoW | Beclomethasone Dipropionate, BDP, Glycopyrronium Bromide, glycopyrrolate, GB, Formoterol Fumarate, FF | Chiesi Farmaceutici S.p.A. | COPD, COPD Exacerbation | 01/26 | 01/26 | | |
TRIPLAR, NCT06234345: Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease |
|
|
| Not yet recruiting | 3 | 986 | RoW | Fluticasone 250mcg/Formoterol 12mcg/Glycopyrronium 25mcg, Fluticasone Propionate 250 mcg/Formoterol Fumarate dihydrate 12 mcg/Glycopyrronium Bromide 25 mcg, Comparator - Trimbow®, Trimbow® - Beclomethasone Dipropionate 100 mcg/Formoterol Fumarate dihydrate 6 mcg/Glycopyrronium Bromide 12.5 mcg | Eurofarma Laboratorios S.A. | Chronic Obstructive Pulmonary Disease | 11/27 | 07/28 | | |
